知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

32 records (took 0.025 seconds)

    Monitoring Cancer Stem Cells
    1.
    发明公开
    Monitoring Cancer Stem Cells 审中-公开

    公开(公告)号：US20230324391A1

    公开(公告)日：2023-10-12

    申请号：US17985558

    申请日：2022-11-11

    Applicant: Stemline Therapeutics, Inc.

    Inventor： Ivan Bergstein ,  Thomas P. Cirrito

    IPC: G01N33/574 ,  G01N33/50

    CPC classification number: G01N33/574 ,  G01N33/5073 ,  G01N33/57492 ,  G01N2800/52

    Abstract: The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient. The present invention also provides for a method of treatment of cancer, wherein such method involves the use of a therapeutic agent that stabilizes or reduces the amount of cancer stem cells in or from a patient.

    IL3Ralpha antibody conjugates and uses thereof
    3.
    发明授权
    IL3Ralpha antibody conjugates and uses thereof 有权

    公开(公告)号：US10906979B2

    公开(公告)日：2021-02-02

    申请号：US16393863

    申请日：2019-04-24

    Applicant: STEMLINE THERAPEUTICS, INC.

    Inventor： Ivan Bergstein

    IPC: C12N15/86 ,  C07K16/28 ,  C12N9/10 ,  C12N5/10 ,  A61K39/00 ,  C07K16/18 ,  C12N5/16

    Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.

    MONITORING CANCER STEM CELLS
    5.
    发明申请
    MONITORING CANCER STEM CELLS 审中-公开

    公开(公告)号：US20170146536A1

    公开(公告)日：2017-05-25

    申请号：US15215727

    申请日：2016-07-21

    Applicant: Stemline Therapeutics, Inc.

    Inventor： Ivan Bergstein ,  Thomas P. Cirrito

    IPC: G01N33/574

    CPC classification number: G01N33/574 ,  G01N33/5073 ,  G01N33/57492 ,  G01N2800/52

    Abstract: The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient. The present invention also provides for a method of treatment of cancer, wherein such method involves the use of a therapeutic agent that stabilizes or reduces the amount of cancer stem cells in or from a patient.

    Methods for Treating Centronuclear Myopathy
    8.
    发明申请
    Methods for Treating Centronuclear Myopathy 有权

    公开(公告)号：US20220202824A1

    公开(公告)日：2022-06-30

    申请号：US17275293

    申请日：2019-09-13

    Applicant: Stemline Therapeutics, Inc.

    Inventor： Enrique Poradosu ,  Thomas Bartholomew Crabbe

    IPC: A61K31/5377

    Abstract: Disclosed herein are methods for treating centronuclear myopathies, such as myotubular myopathy, in a subject in need thereof, comprising administering to the subject in need thereof an effective amount of 3-{[(3S)-4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)morpholin-3-yl]methyl}-N,N,1-trimethyl-1H-indole-5-carboxamide and/or a pharmaceutically acceptable form thereof.

    Methods of Manipulating the Fate of Cells
    9.
    发明申请
    Methods of Manipulating the Fate of Cells 有权

    公开(公告)号：US20210388354A1

    公开(公告)日：2021-12-16

    申请号：US17157131

    申请日：2021-01-25

    Applicant: Stemline Therapeutics, Inc.

    Inventor： Ivan Bergstein

    IPC: C12N15/113 ,  A61K45/06 ,  A61K31/7088 ,  C12N15/11 ,  A61K31/7105 ,  A61K31/713 ,  C12Q1/6886

    Abstract: A method of manipulating the fate of a cell, which comprises contacting the cell with at least one of (a) a cell fate-determining untranslated/noncoding RNA species (cuR), (b) a modified cuR, or (c) a compound that modifies or affects cuR, under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained. Another aspect of the invention relates to a method of manipulating the fate of a cell by contacting the cell with a compound that affects a fate-determining mechanism involving homologous nucleic acid interactions of RNA:RNA or RNA:DNA or resolution of such interactions under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained. The invention generates cell fate or cell maintenance in a subject, such as a human, so that an increase of desirable cells or a decrease in undesirable cells can be obtained in the subject. This feature can be applied to a therapeutic method of treating a condition in a subject.

    IL3Ralpha Antibody Conjugates and Uses Thereof
    10.
    发明申请
    IL3Ralpha Antibody Conjugates and Uses Thereof 审中-公开

    公开(公告)号：US20190315874A1

    公开(公告)日：2019-10-17

    申请号：US16393863

    申请日：2019-04-24

    Applicant: STEMLINE THERAPEUTICS, INC.

    Inventor： Ivan Bergstein

    IPC: C07K16/28 ,  C12N9/10 ,  C12N15/86

    Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.

Patent Agency Ranking